$CHWY

Nasdaq Surges Over 100 Points; Chewy Shares Fall After Q2 Results - Chewy (NYSE:CHWY), Cuprina Holdings (Cayman) (NASDAQ:CUPR)

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.17% to 45,632.29 while the NASDAQ rose 0.53% to 21,995.12. The S&P 500 also rose, gaining, 0.64% to 6,554.06.

Original reporting
Benzinga · Avi Kapoor
Published Sep 10, 2025, 2:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 10, 2025, 3:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nasdaq Surges Over 100 Points; Chewy Shares Fall After Q2 Results - Chewy (NYSE:CHWY), Cuprina Holdings (Cayman) (NASDAQ:CUPR) — source image
Decision brief

The 30-second read

$CHWYNeutralLow
01

Why it matters

While the overall market sentiment is positive, individual stocks like Chewy are reacting cautiously to earnings, indicating sector-specific risks.

02

Market read

The news indicates a cautiously optimistic market environment with mixed company-specific reactions, suggesting limited immediate trading opportunities but potential for short-term adjustments.

03

What to watch

Broader economic indicators and upcoming earnings reports could influence market direction more significantly than this news.

Timing: short-term

Background

The U.S. stock market experienced a rally, with the Nasdaq gaining over 100 points amid mixed earnings reports.

Company-level read

Ticker impact

$CHWYNeutralMedium confidence
Context

The news mentions Chewy's Q2 results and its stock performance.

Expected impact

Potential short-term decline of 2-4% in Chewy's stock, with stabilization expected over the next week.

Evidence & confidence

The decline post-earnings suggests a cautious market reaction, but no significant long-term trend is indicated.

$CUPRBullishMedium confidence
Context

The news highlights Cuprina Holdings' stock movement amidst the market rally.

Expected impact

Potential short-term increase of 1-3%, with room for further gains if market conditions remain favorable.

Evidence & confidence

Market momentum supports a modest upward move, but company-specific factors are not detailed.

Market effects

The mixed earnings and market rally suggest cautious optimism in retail, technology, and financial sectors.

U.S. market rally indicates positive regional sentiment.

Limited, as the news focuses on U.S. markets and specific companies.

Counterpoint

The market rally may be overextended; a short-term correction could occur, especially if earnings disappoint further.

Key entities

  • Chewy

    An online retailer of pet food and supplies.

  • Cuprina Holdings

    A company involved in the pharmaceutical or chemical sector, based on context.

Related articles

$RDDTMed

Reddit Vs. Chewy: The Better Buy Stock In 2026

Reddit (NYSE: RDDT) reported Q1 revenue of $663.41M (+74% YoY) and adjusted EBITDA margin of 40.1%, with ad revenue $625M and 126.8M daily uniques; CEO cited AI licensing partnerships with Google and OpenAI. Chewy (NYSE: CHWY) reported Q1 revenue $3.357B (+7.7%), gross margin 30.1%, and autoship $2.833B (84.4% of sales).

$CHWYMed

Why Is Chewy (CHWY) Stock Soaring Today

Chewy (CHWY) shares rose about 5.5% after the company said it is expanding AI and automation across customer service, pharmacy, fulfillment and marketing. Chewy built the infrastructure in Q1 FY2026 and expects efficiency benefits in the low tens of millions of dollars in FY2026, with more in 2027+.

$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

$CHWYMed

Is Chewy Stock a Buy as Revenue and Margins Continue to Grow?

Chewy reported fiscal Q1 revenue of $3.36 billion, up 7.7%, and adjusted EPS of $0.43, up 23%, meeting consensus, according to the article. Active customers rose to 21.5 million and gross margin increased to 30.1%. Chewy raised adjusted EBITDA to $253.1 million but slightly lowered full-year revenue guidance to $13.40–$13.55 billion, citing a more cautious consumer.